Short Reads

First Dutch excessive pricing case in pharma may be expected soon

First Dutch excessive pricing case in pharma may be expected soon

First Dutch excessive pricing case in pharma may be expected soon

26.03.2018 NL law

On 7 March 2018, the president of the Dutch Authority for Consumers and Markets (ACM) together with two colleagues published a paper concerning the application of the competition rules in the pharmaceutical industry.

 

The paper specifically explains that they see a role for competition law enforcement if the owners of patented drugs engage in excessive pricing. In its agenda 2018-2019 published earlier this year, the ACM indicated that it will focus on four topics, one of which will be the price of pharmaceuticals [see our March 2018 Newsletter]. The latest paper could be seen as a follow-up on the issue and it seems likely that the ACM is looking for a case to pursue in the area.

The focus of the paper is on excessive pricing and introduces at least two positions that are noteworthy. First, the authors argue that they see no objection in principle to a finding of excessive pricing in cases where the relevant drug is still patent protected. This is interesting as competition enforcers that have previously pursued excessive pricing cases in the pharma setting have so far focused on drugs that had been off-patent for quite a while and for which the owner then quite suddenly implemented a massive price increase (e.g. the cases of Pfizer in the UK, Aspen in Italy and in the EU). A possible reason for an enforcement focus on off-patent price hikes could be that in such cases the risk of competition law enforcement getting entangled with innovation incentives may be less pronounced. This is because in off-patent scenarios sufficient time has often elapsed for innovators to recoup their investment and make a profit. The authors note, however, that also in cases where the patent is still in place there are ways to strike the right balance between acceptable price levels and innovation incentives.

Relatedly, the authors point towards a possible framework for deciding which excessive pricing cases they should pursue in relation to patented drugs that would also take into account innovation incentives. The authors argue that simply pursuing cases where the price is above the relevant ‘quality of life adjusted year’ (qualy) threshold should strike the right balance as it would incentivise producers to ‘focus on socially relevant products’ only (p. 13 of the paper). This threshold varies in the Netherlands depending on the severity of the disease, up to a maximum value of EUR 80,000 per qualy. The authors were quick to note, however, that prices below qualy are not necessarily non-excessive (p. 14 of the paper).

Now that the ACM seems to be moving towards an established framework for pursuing excessive pricing cases, one wonders whether the regulator is gearing up to actually commencing an enforcement action in the area. There are at least three reasons to expect that this is likely. First, experience shows that ACM is likely to turn priorities identified in its agenda into actual cases. Secondly, an excessive pricing case would fit the political climate – prevalent throughout Europe but certainly also in the Netherlands – that demands action against high prices for ‘sensitive’ drugs. Finally, the paper references an ACM working paper that is still a work in progress, which sets out in more detail the qualy-threshold based framework as a basis for excessive pricing cases. These reasons could be seen as signals that the ACM is preparing to get active in this space.

 

This article was published in the Competition Law Newsletter of April 2018. Other articles in this newsletter:

1.       District Court rules on the preliminary defences in CRT case

2.       District Court Amsterdam rules real estate platform Funda did not abuse its dominant position

Team

Related news

07.11.2019 NL law
Safeguarding legal privilege: better safe than sorry?

Short Reads - The European Court of Justice recently ruled that the European Commission does not have to take additional precautionary measures to respect the right of legal professional privilege when conducting a new dawn raid at the same company. Companies are well-advised to mark clearly all communications covered by legal privilege as 'privileged and confidential' and to keep all privileged communication separate from other communication.

Read more

12.11.2019 EU law
Third country bids in EU procurement: always excluded?

Articles - The European Commission recently issued guidance on the participation of third country bidders in public procurement. It clarified bids may be excluded, but remains silent on whether they may be accepted and under which conditions. The Commission is of the opinion that contracting authorities or entities can exclude bids if no access is secured. However, it does not discuss if and under which conditions contracting authorities or entities can allow foreign bids if no access is secured.

Read more

07.11.2019 NL law
Tackling Big Tech up-front? Time to stop thinking and start acting

Short Reads - Benelux competition authorities have published a joint memorandum on how best to keep up with challenges in fast-moving digital markets. As well as calling on the European Commission to issue an economic study on digital mergers, the memorandum calls for an ex ante intervention tool to fill the gap between interim measures and ex post enforcement. This tool would pre-emptively impose behavioural remedies on digital gatekeepers without first having to establish an actual competition law infringement.

Read more

08.11.2019 BE law
Interview with Wouter Ghijsels on Next Gen lawyers

Articles - Stibbe’s managing partner Wouter Ghijsels shares his insights on the next generation of lawyers and the future of the legal profession at the occasion of the Leaders Meeting Paris where Belgian business leaders, politicians and inspiring people from the cultural and academic world will discuss this year's central theme "The Next Gen".

Read more

07.11.2019 NL law
Rotterdam District Court rules that claims in elevator cartel damages proceedings need further substantiation

Short Reads - The Rotterdam District Court has ordered claimant SECC (a litigation vehicle) to substantiate its claims in proceedings against Kone and ThyssenKrupp regarding the elevator cartel. The Court also ruled that some claims have become time-barred, unless SECC can show that these were timely assigned to SECC and notified to Kone and ThyssenKrupp. The Court rejected several defences of Kone and Thyssenkrupp, including a jurisdictional challenge based on arbitration clauses between the defendants and assignors of claims to SECC.

Read more

Our website uses functional cookies for the functioning of the website and analytic cookies that enable us to generate aggregated visitor data. We also use other cookies, such as third party tracking cookies - please indicate whether you agree to the use of these other cookies:

Privacy – en cookieverklaring